EHA2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Relapsed/refractory (R/R) FL has a progressively worsening prognosis with each subsequent relapse and no curative treatment options. The early results of the Phase II ELM-2 trial evaluating Regeneron's Odronextamab as a new treatment for R/R FL were presented at the European Hematology Association Congress (EHA2024). Odronextamab is a novel bispecific T-cell engager (BiTE) that targets CD20 on B cells and CD3 on T cells, providing T-cell-mediated cytotoxicity towards cancer cells. In the ELM-2 trial, 128 heavily pretreated R/R FL patients received intravenous Odronextamab in 21-day cycles until disease progression or intolerable toxicity. At a median efficacy follow-up of 20 months, the objective response rate was 80.5% and the complete response (CR) rate was 73.4%, indicating that most patients achieved significant tumour reduction. The responses were notably durable, with a median duration of response of 21 months and a median duration of CR at 25.1 months. Furthermore,
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Day One targets the growing ADC market with MabCare acquisition [Yahoo! Finance]Yahoo! Finance
- EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]Yahoo! Finance
- Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics) [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at Truist Financial Co. from $50.00 to $53.00. They now have a "buy" rating on the stock.MarketBeat